Background
==========

Postoperative analgesia is an important issue in general surgery due to its close association with patients' early recovery. Although laparoscopic liver resection uses a smaller incision and causes less pain compared with open surgery, postoperative pain still affects the prognosis of some patients. Use of analgesia drugs is the most common method for analgesia; among these drugs, fentanyl holds the dominant position. Because fentanyl has no ceiling effect, increasing the drug dose can strengthen the effect, no matter how severe the pain is \[[@b1-medscimonit-24-8224]\]. Nonetheless, increasing the dose can increase risk of adverse effects like nausea, emesis, and respiratory inhibition. Intrathecal fentanyl has been proved to be effective in laparoscopic abdominal surgery. However, the delayed onset effect limits its application. Therefore, an alternative method is needed to solve this problem.

Parecoxib sodium is the first COX-2 inhibitor that can be administered by intravenous and intramuscular injection. Numerous clinical trials have demonstrated the excellent efficacy of parecoxib in orthopedics, general surgery, and gynecology \[[@b2-medscimonit-24-8224]--[@b4-medscimonit-24-8224]\]. Research shows that parecoxib plays an important role in the perioperative and postoperative period, especially in patients about to undergo abdominal surgery. Moreover, increasing the dose rarely causes adverse effects. Therefore, parecoxib is a promising drug for postoperative pain management.

Effective control and management of postoperative pain is the primary concern of patients and is also important to surgeons because of potential adverse effects of the physiologic response to pain after surgery. Severe pain leads to reduced patient satisfaction and increased morbidity and mortality, and it places a burden on patient and health system finances. Inadequately controlled pain negatively affects quality of life, function, and functional recovery \[[@b5-medscimonit-24-8224]\]. Therefore, postoperative pain management is one of the most important issues throughout the perioperative period, and researchers are devoting themselves to developing optimal methods to control postoperative pain and thus enhance recovery after surgery. PCA (patient-controlled analgesia) was initially developed due to insufficient pain relief from conventional intramuscular delivery of opioids \[[@b6-medscimonit-24-8224]\]. PCA has now become widely prescribed for pain management \[[@b7-medscimonit-24-8224]\]. It offers greater analgesic efficacy and potentially fewer adverse events than intermittent administration because of the ability of patients to titrate generally smaller on-demand doses according to their own needs rather than receiving analgesics intravenously several times a day.

Thus, we hypothesized that using a new patient-controlled analgesic system with an intravenous infusion pump would significantly improve postoperative pain management compared to use of a conventional intravenous infusion pump for patient-controlled analgesia. This controlled, prospective, randomized trial was performed to evaluate the benefit of a new type of intravenous infusion pump for patient-controlled analgesia and also the advantage of parecoxib as analgesic compared with fentanyl for postoperative analgesia after laparoscopic liver resection.

This study is registered on the *[ClinicalTrial.gov](http://ClinicalTrial.gov)*. The number is NCT02408146.

Material and Methods
====================

Patients
--------

We enrolled 124 patients aged 18--75 years old who were scheduled for laparoscopic liver resection. Informed consent was obtained from each patient prior to biopsy or surgery, and ethics approval for the use of human subjects was obtained from the Research Ethics Committee of the First Affiliated Hospital of Harbin Medical University. Patients who had contraindications to designated drugs (morphine, fentanyl, and parecoxib), chronic pain, and history of drug dependence or sleep apnea syndrome are excluded from this study. Patients were randomly separated into 3 groups -- a fentanyl (FEN) group, an intravenous parecoxib (IVPA) group, and a parecoxib pump (PUPA) group -- by use of a computerized randomization table. The patients, anesthesiologist, surgeon, research nurse, and the stuff in the ward or the surgical unit were blind to the group assignment of the patients.

Preoperative treatment
----------------------

Patients did not get any premedication while they were in the ward, but all received midazolam 0.05 mg per kilogram intravenously in the operating room. Patients' monitoring was standardized and consisted of oximetry, PaCO~2~, 3-lead electrocardiogram, blood pressure monitoring, and continuous CVP. All patients had a peripheral intravenous drip, urinary catheter (no longer than 3 days), and a nasogastric tube.

Anesthesia
----------

All patients received intravenous-inhalation combined anesthesia. Induction was begun with sufentanil 0.4 μg/kg bolus and was maintained by an infusion of 0.2 μg/kg per hour. Sufentanil was stopped 30 min before the surgery finished. Induction was maintained with propofol 1.0 to 2.0 mg per kilogram, and rocuronium 0.6 mg per kilogram when needed. After tracheal intubation, anesthesia was maintained with a mixture of air and oxygen (0.5 L/0.5 L) and desflurane 0.6 to 1 minimum alveolar concentration. Additional boluses of sufentanil 0.05 μg/kg were monitored at 5-min intervals if current arterial pressure was over 20% higher than the baseline value. If arterial pressure was under 20% of baseline value, phenylephrine infusion was added to maintain it.

Surgical technique
------------------

Liver resection used 4 ports (10 mm and 3×5 mm) based on the location of the liver. After anesthesia, doctors use carbon dioxide to fill suffused patients' abdominal cavity with a maximal pressure of no more than 15 mmHg. Patients were placed in a 30-degree Fowler position during liver resection. The specimen after resection was removed through an incision about 7 cm long.

Postoperative treatments
------------------------

After the surgery, the FEN group received patient-controlled analgesics (fentanyl citrate 20 μg/mL·kg + ondansetron hydrochloride 2 mg per mL +saline solution) with a conventional intravenous infusion pump for 3 days after liver resection. The pump infused continuously at the basic flow rate of 2 mL per h, at which 0.5 mL of bolus is injected into patients if the patients press the button while they are suffering from postoperative pain. The lock-out time for each bolus injection is 15 min. The IVPA group patients received oral celecoxib before surgery, then received 40 mg parecoxib sodium intravenously guttae twice a day for the next 3 days after surgery. For the IVPA group, we used a targeted-controlled infusion (TCI) pump for pain management. TCI utilizes a computer-controlled infusion pump to deliver analgesic according to the set-up by the administering physician. The PUPA group received oral celecoxib every day before surgery, and received 40 mg parecoxib sodium intravenously guttae as soon as the surgery finished, then the patients wore the new intravenous infusion pump for patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for 3 days after surgery. The pump infuses continuously with the basic flow rate of 2 mL per h, at which 0.5 mL of bolus will be injected into patients if the patients press the button while they are suffering from postoperative pain. The lock-out time is 15 min for each bolus injection. When the patients received the pump, the analgesic inside the pump and the dosage of the medicine were already set by the researcher. These methods were all initiated before patients were sent back to the ward. Therefore, it the medical staff were blind to group assignments.

While using the PCA pump, patients' respiration (respiratory rate and oxygen saturation) was monitored at every hour for the first 24 h and every 2 h thereafter. If blood saturation was lower than 95%, supplemental oxygen by nasal prongs was provided for the patients.

Clinical outcome
----------------

The primary outcome was pain scores. Pain scores were evaluated with a VAS of 0 to 10, which is measured at rest and with movement like walking, coughing, and deep breathing. We also used the Bruggeman comfort scale to assess postoperative pain.

The secondary outcomes were sedation, nausea, and respiration. Sedation, nausea, and pruritus were measured as well at 2, 4, 8, 16, 24, 48, and 72 h after patients were back in the ward. All the data were collected and recorded by the same research nurse. We also recorded whether pain affected patients' movement and sleep, divided into 5 levels: no effect, affecting sleep, unable to sleep, unable to eat, and limited self-care ability.

Rescue medication
-----------------

Rescue medication consisted of diphenhydramine 25 mg through intravenous drip every 8 h for pruritus, metoclopramide 10 mg IV every 8 h if patients suffer had nausea or vomiting, and, if the therapy above is ineffective, ondansetron 4 mg IV every 8 h. If patients in the ward could not bear the pain after surgery and other analgesics were ineffective, dolantin (50 mg) was used once.

Statistics analyze
------------------

Data are expressed as mean ± standard deviation for continuous variables and median and interquantile range for categorical variables. To ensure statistical was done correctly, distribution of data was examined. VAS was analyzed as a nonparametric variable for its non-normal distribution. VAS score was analyzed by *t* test and one-way ANOVA. The secondary outcome was assessed as categorical variables and were analyzed by Mann-Whitney U test. All patients' characteristics were analyzed by *t* test, Shapiro-Wilk test and D'Agostino test. All statistical analysis was performed with SPSS19.0 (SPSS, Inc., Chicago, IL) and GraphPad Prism6.

Result
======

Patients and characteristics
----------------------------

In this study, 124 patients participated in and completed the study. All of the 3 groups had similar demographic characteristics and their baseline laboratory values had no significant difference. There was no significant difference among the groups with regard to age, sex, ASA level, height, or weight ([Table 1](#t1-medscimonit-24-8224){ref-type="table"}). All variables except ASA levels were normally distributed as assessed by Shapiro-Wilk test and D'Agostino test. There were no significant differences in duration of surgery, time to extubation, urine output, or blood loss among the 3 groups. All patients were extubated in the operating room and no patient was transferred to the ICU for further treatment.

VAS scores
----------

The primary outcome of this study was the pain score as evaluated by VAS. The data ([Figure 1](#f1-medscimonit-24-8224){ref-type="fig"}) demonstrated that VAS scores at rest in the IVPA and PUPA groups were significantly lower than in the FEN group (P\<0.001) at all time intervals, and VAS of the PUPA group was lower compared with the IVPA group. Similar results ([Figure 2](#f2-medscimonit-24-8224){ref-type="fig"}) were achieved for VAS score with movement ([Table 2](#t2-medscimonit-24-8224){ref-type="table"}). We conclude that patients using parecoxib as analgesic suffered less pain compared to patients using fentanyl, and we found that using the PCA pump helps relieve postoperative pain.

Adverse effects
---------------

We also investigated adverse effects, which was selected as the secondary outcome. The adverse effects we measured included sedation, nausea, pruritus, and respiratory rate. We found that nausea scores in the FEN group were significantly higher than in the IVPA group and PUPA group at 2, 4, and 8 h ([Table 3](#t3-medscimonit-24-8224){ref-type="table"}). Moreover, the sedation score of the FEN group was markedly higher than that in the IVPA and PUPA groups at 2 h, 4 h, 8 h, and 16 h. Hence, we found that patients using parecoxib as analgesic had fewer adverse effects.

Application of dolantin
-----------------------

Some patients suffer unbearable pain that requires dolantin to relieve; therefore, we also accessed the effect of dolantin in each group. Eight patients in the FEN group required dolantin, while only 1 in the IVPA group and 2 in the PUPA group required dolantin, suggesting the better efficacy of parecoxib for analgesia compared to FEN ([Table 4](#t4-medscimonit-24-8224){ref-type="table"}).

Quality of life
---------------

Quality of life during the perioperative period is another important factor that can be affected by postoperative pain. In this study, we detected significant differences in sleeping quality among the 3 group ([Table 5](#t5-medscimonit-24-8224){ref-type="table"}). In the FEN group, 20 patients reported that their sleeping quality was affected by pain and 10 patients complained that they could not sleep due to unbearable pain. Thirteen patients in the IVPA group and 15 patients in the PUPA group reported that their sleep quality was slightly affected by pain, and only 6 patients in the IVPA group and 7 patients in the PUPA group patients reported that they could not sleep. No patients complained that they could not asleep at all. Altogether, our results demonstrate that parecoxib has better analgesic efficacy than FEN.

Discussion
==========

Laparoscopic surgery is becoming a common therapeutic option for liver cancer. Although laparoscopic surgery is less painful than normal open surgery, postoperative pain after laparoscopic surgery still is a problem that affects 17% to 41% of patients \[[@b8-medscimonit-24-8224]\]. Moreover, the postoperative pain leads to delay of early ambulation after surgery, thereby resulting in delayed recovery from surgery. Therefore, various strategies were developed to solve this problem, including use of intrathecal morphine and other oral or intravenous analgesics \[[@b9-medscimonit-24-8224]\]. However, the efficacy of these analgesics differs, and they may be used according to pain properties, such as type, location, and duration. There have been few studies on analgesia in laparoscopic liver resection, and there is debate about the best strategies for postoperative analgesia; therefore, there is an urgent need to develop novel methods to solve this problem.

Opioid analgesics are the most widely used drugs for controlling postoperative pain, but they may cause nausea, vomiting, and addiction \[[@b10-medscimonit-24-8224]\]. Some researchers have attempted to use other analgesics, such as paracetamol, ketoprofen, and parecoxib, to improve postoperative pain management, but they found that these analgesics have the same problems as opioids \[[@b11-medscimonit-24-8224]--[@b14-medscimonit-24-8224]\].

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been proved to have effects similar to those of opioids \[[@b15-medscimonit-24-8224]\]. NSAIDs are a well-established class of drugs that have been used for the blockage of pain and inflammation. They can maintain a constant level of prostaglandin inhibition over the course of prolonged surgery and during the postoperative period. Thus, we speculate that NSAIDs could be an alternative for opioids due to having fewer adverse effects.

Non-selective NSAIDs can inhibit COX-1 and COX-2, which are isoenzymes that play an important role in prostaglandin synthesis. Specific inhibition of COX-2 provides anti-inflammatory effects, while inhibition of COX-1 results in gastrointestinal adverse effects. Some researchers have confirmed that selective COX-2 inhibitors may be associated with better gastrointestinal tolerance and comparable cardiovascular events \[[@b16-medscimonit-24-8224]\]. Therefore, it is inappropriate to apply orally administered NSAIDs in cases of postoperative nausea and vomiting or where the oral route of administration is inaccessible after surgery. Some researchers have confirmed that selective COX-2 inhibitors may be associated with better gastrointestinal tolerance and comparable cardiovascular events \[[@b17-medscimonit-24-8224]\]. Therefore, using the new selective COX-2 inhibitor, parecoxib, intravenously, could avoid some adverse effects. Nevertheless, these adverse effects may not be problematic with the short-term administration of parecoxib in patients who have normal renal function and normal cardiac function, as shown in our study. Parecoxib is a first COX-2 inhibitor for parenteral administration, and can be given either intravenously or intramuscularly, providing potential advantages over oral medication. Studies have shown that it is the only parenterally administered selective COX-2 inhibitor that has proven analgesic effects \[[@b18-medscimonit-24-8224]\].

We performed a randomized, double-blind study to investigate whether parecoxib has advantage over fentanyl, and to assess the advantages of PCA pumps. We used a patient-controlled analgesia pump with a lock time that is 15 min. With this PCA pump we can control the dose of parecoxib and fentanyl to prevent overdose, which can affect the conscious state of patients and can cause more serious adverse effects. All of the above considerations result in longer recovery time after laparoscopic surgery ([Figure 3](#f3-medscimonit-24-8224){ref-type="fig"}).

Our results show that the intravenous parecoxib group and the parecoxib pump group felt less pain after surgery. VAS at rest or with movement in the IVPA and PUPA groups were lower than in the group fentanyl, with less adverse effects. Sedation and nausea were more frequent in the group receiving fentanyl. Some researchers have found that overuse of opioids can be associated with troublesome complications, including depression, hemodynamic instability, nausea, vomiting, prolonged sedation, respiratory depression, and ileus \[[@b19-medscimonit-24-8224]--[@b21-medscimonit-24-8224]\]. Moreover, the sedation caused by opioids impede treatment of patients after surgery \[[@b22-medscimonit-24-8224]\]. The VAS scores and adverse effects suggest that parecoxib has more beneficial effects than fentanyl in patient undergoing laparoscopic liver resection.

Opioid-induced hyperalgesia (OIH) is a problem that may arise in patients treated with opioids, in which patients receiving opioids to control pain somewhat paradoxically become more sensitive to pain as a direct result of opioid therapy. In our study, induction was begun with sufentanil 0.4 μg per kilogram bolus followed by an infusion of 0.2 μg/kg per hour. Thus, our patients had an opportunity to have OIH. Two controlled studies reported aggravated postoperative pain despite increased postoperative opioid consumption in patients receiving a high rather than a low systemic opioid dose during surgery \[[@b23-medscimonit-24-8224],[@b24-medscimonit-24-8224]\]. Some studies found that N-methyl-D-aspartate receptors (NMDA) is involved in this mechanism. The activation of NMDA may cause the phenomenon of OIH \[[@b25-medscimonit-24-8224],[@b26-medscimonit-24-8224]\]. Parecoxib, as a COX-2 inhibitor, can inhibit PGE2 generation. Therefore, parecoxib can indirectly inhibit the NMDA by reducing the amount of PGE2. This mechanism could partly explain why the VAS scores of the PUPA and IVPA groups were lower. Our results suggest that parecoxib can alleviate postoperative hyperalgesia after opioid anesthesia.

Conclusions
===========

We found that use of an intravenous infusion pump for patient-controlled analgesia provided superior analgesic efficacy after laparoscopic liver resection. Using the parecoxib PCA pump can significantly reduce the VAS scores both at rest and with movement. It can also reduce the adverse effects. Patients using the parecoxib pump had higher satisfaction with pain management after laparoscopic liver resection.
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VAS

:   visual analogue scale

ASA

:   America Society of Anesthesiologists

FEN

:   fentanyl group

PUPA

:   parecoxib pump group

IVPA

:   intravenously parecoxib group

PCA

:   patient-controlled analgesia

NSAID

:   nonsteroidal anti-inflammatory drugs

CVP

:   central venous pressure

Sedation Score (Ramsey)
=======================

1 for wide awake. 2 for drowsy. 3 for dozing. 4 for mostly sleeping. 5 for needs stimulation to rouse.

Nausea Score
============

0 for no nausea. 1 for mild nausea. 2 for discomforting nausea. 3 for distressing nausea. 4 for horrible nausea. 5 for worst possible nausea.

Itchiness Score
===============

0 for no itchiness. 1 for mild itchiness. 2 for discomforting itchiness.

![VAS score at rest for each time interval. \* Difference is significant. The VAS score of patients in the IVPA and PUPA groups was significantly lower than that in the FEN group (P\<0.001) at all time intervals (P\<0.001). There is no difference in VAS scores between the IVPA and PUPA groups. The P values are 0.508 at 2 h, 0.698 at 4 h, 0.998 at 8 h, 0.527 at 16 h, 0.638 at 24 h, 0.785 at 48 h, and 0.769 at 72 h.](medscimonit-24-8224-g001){#f1-medscimonit-24-8224}

![VAS score with movement for each time interval. \* Difference is significant. The VAS score of patients in the IVPA and PUPA groups was significantly lower than that in the FEN group (P\<0.001) at all time intervals (P\<0.001). There is no VAS score difference in the IVPA and PUPA groups. The P values are 0.899 at 2 h, 0.376 at 4 h, 0.462 at 8 h, 0.541 at 16 h, 0.884 at 24 h, 0.577 at 48 h, and 0.798 at 72 h.](medscimonit-24-8224-g002){#f2-medscimonit-24-8224}

![The remaining 124 patients were included in randomization and data analysis.](medscimonit-24-8224-g003){#f3-medscimonit-24-8224}

###### 

Patient characteristics for each group.

  Variables                             Fentanyl   IVPA       PUPA
  ------------------------------------- ---------- ---------- ----------
  Age (years)                           50 (15)    52 (11)    51 (13)
  Sex (% male)                          47.5       47.6       52.4
  Weight (kg)                           71 (14)    76 (15)    73 (16)
  Height (cm)                           165 (7)    167 (9)    168 (7)
  ASA (II/III/IV)                       14/20/6    12/21/9    14/22/6
  Starting Hb value (g/L)               136 (11)   133 (12)   130 (10)
  Starting platelet count, 10^9^ pl/L   245 (44)   254 (47)   251 (46)

Values are mean (SD), otherwise absolute number. All the P values of the statistical are nonsignificant. All the varieties except ASA level follow the normal distribution. w \<0.919

###### 

VAS scores after surgery during 72 h.

  Variables      Time points   Group FEN     Group IVPA    Group PUPA
  -------------- ------------- ------------- ------------- -------------
  Rest VAS       2 h           3.600±1.392   2.690±0.890   2.310±0.749
  4 h            4.000±1.414   2.548±0.539   2.000±0.584   
  8 h            3.625±1.580   2.381±0.803   1.881±0.670   
  16 h           3.200±1.091   2.048±0.739   1.452±0.663   
  24 h           3.050±1.449   1.762±0.701   1.333±0.687   
  48 h           2.350±1.189   1.667±0.853   1.119±0.739   
  72 h           2.500±1.359   1.381±0.670   0.929±0.808   
  Movement VAS   2 h           4.175±1.500   3.214±0.891   2.738±0.828
  4 h            4.200±1.436   2.952±0.705   2.595±0.767   
  8 h            3.825±1.615   2.786±0.708   2.405±0.767   
  16 h           3.300±1.159   2.500±0.796   1.905±0.617   
  24 h           3.450±1.431   2.262±0.656   1.738±0.828   
  48 h           2.875±1.418   2.238±1.037   1.619±0.909   
  72 h           2.550±1.260   1.833±0.928   1.381±0.764   

Data are expressed as mean ±SD. All the P value of group FEN and group IVPA are \<0.001. All the P value of group FEN and group PUPA are \<0.001. All the P value of group PUPA and group IVPA are \<0.001. The statistics were analyzed by *t* test and one-way ANOVA test.

###### 

Median evaluation of adverse effects for each group.

  Hours   Sedation (1--5)   Nausea (0--5)   Pruritus (0--2)                                           
  ------- ----------------- --------------- ----------------- ------- ------- ------- ------- ------- -------
  2       3 (2)             1 (1)           1 (1)             2 (2)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)
  4       2 (2)             1 (1)           1 (1)             2 (1)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)
  8       3 (2)             1 (0)           1 (0)             1 (1)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)
  16      2 (2)             0 (0)           1 (1)             1 (1)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)
  24      1 (1)             0 (0)           0 (0)             0 (0)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)
  48      1 (0)             1 (1)           0 (0)             0 (0)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)
  72      1 (1)             0 (0)           0 (0)             0 (0)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)

Data are expressed as median (interquartile range). Mann-Whitney U test was used to analyze data. Scoring is according to the Sedation Score (Ramsey).

###### 

Number of times dolantin was used.

  Groups       Times dolantin used
  ------------ ---------------------
  Group FEN    8
  Group IVPA   2
  Group PUPA   1

Values are absolute numbers.

###### 

Patients' movement situation affected by the pain.

  Group        No effect   Affecting sleep   Unable to sleep   Unable to eat   Limited self-care ability
  ------------ ----------- ----------------- ----------------- --------------- ---------------------------
  Group FEN    5           20                10                3               2
  Group IVPA   21          13                6                 1               1
  Group PUPA   18          15                7                 1               1

Values are absolute numbers.
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